Silencing of CEBPB-AS1 modulates CEBPB expression and resensitizes BRAF-inhibitor resistant melanoma cells to vemurafenib

Introduction of targeted therapy in the treatment of metastatic cutaneous malignant melanoma (CMM) has improved clinical outcome during the last years. However, only in a subset of the CMM patients, this will lead to long-term effects. CEBPB is a transcription factor that has been implicated in vari...

Descripción completa

Detalles Bibliográficos
Autores principales: Vidarsdottir, Linda, Fernandes, Rita Valador, Zachariadis, Vasilios, Das, Ishani, Edsbäcker, Elin, Sigvaldadottir, Ingibjorg, Azimi, Alireza, Höiom, Veronica, Hansson, Johan, Grandér, Dan, Egyházi Brage, Suzanne, Pokrovskaja Tamm, Katja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2020
Materias:
Original Articles: Basic Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7469874/
https://www.ncbi.nlm.nih.gov/pubmed/32467529
http://dx.doi.org/10.1097/CMR.0000000000000675

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7469874/
https://www.ncbi.nlm.nih.gov/pubmed/32467529
http://dx.doi.org/10.1097/CMR.0000000000000675

Ejemplares similares